Dianthus Therapeutics, Inc. /DE/ (DNTH): restructuring charge — Magenta Therapeutics to cut ~84% of workforce, CEO Gardner departs; CFO Mahoney becomes President

Dianthus Therapeutics, Inc. /DE/

Board approved restructuring plan reducing workforce by up to 56 positions (~84%), substantially complete by Feb 17, 2023.
Expected severance and related costs of approximately $5.4 million by end of February 2023.
CEO Jason Gardner, CTO David Nichols, CCO Caren Deardorf, CPO Kristen Stants, and SVP Shawn Rose to leave the company.
CFO/COO Stephen Mahoney named President; Gardner resigns from board effective Feb 7, 2023.
Preliminary cash, cash equivalents, and marketable securities of ~$112M as of Dec 31, 2022 (unaudited).

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ announced a restructuring with charges of $5.4 million (up to 56 positions, or approximately 84%).

Type: restructuring
Charge: $5.4 million
Headcount: up to 56 positions, or approximately 84%

Exact text from the filing

or approximately 84%, to be substantially completed by February 17, 2023. As a result of the Plan, the Company expects to incur estimated severance and related costs of $5.4 million by the end of February 2023. Each departing employee of Magenta has played an integral role in the Company’s mission of improving stem cell transplant to enable access for more

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-23-026931

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.